Obligations of Foreign Manufacturers Entering the United States Market

1. Key takeaways

To enter the United States, a foreign manufacturing enterprise must fulfill seven basic obligations: establishment registration, device listing, a quality management system, a 510(k) (unless exempt) or a PMA, labeling, and medical device reporting (MDR). The seventh obligation, designating a United States Agent (US Agent), is exclusive to foreign enterprises and is the precondition that allows the first six to stand at all. Without an agent in place the registration cannot be completed, and without registration nothing downstream operates. Foreign manufacturers should therefore treat the seven obligations as a single program with internal dependencies, rather than as a menu of tasks that can be picked off in any order or delegated piece by piece to whoever happens to be available.

• FDA does not recognize regulatory authorizations from other countries; the product must meet the applicable FDA regulation regardless of CE or other national approvals.
• Foreign manufacturing facilities are subject to FDA inspection, device tracking where applicable, and adverse event reporting, aligning their duties fully with domestic firms.
• The seven obligations are connected in series: a missing US Agent blocks registration, which blocks listing, which exposes shipments to detention under Import Alert 99-34.
• The QMSR, effective 2026-02-02, anchors the quality management obligation in 21 CFR Part 820.
• Labeling and UDI duties under 21 CFR Parts 801 and 830 apply alongside the premarket and reporting tracks.

2. Legal basis

The table below assembles the regulatory anchors for each of the seven obligations, together with the FDA import guidance that states the governing principle for foreign manufacturers. Every row was checked against its cited source during the verification pass for this article, so the citations can be relied upon as the working reference for the compliance file.

3. Expert insights

Insight one: FDA’s official words are that it does not recognize regulatory authorizations from other countries.

The FDA import page states, in its own words: “The FDA does not recognize regulatory authorizations from other countries. The product must meet the applicable FDA regulation.” This sentence is the master principle behind every obligation that foreign manufacturers carry, and it directly refutes the notion that holding a CE certificate or an NMPA registration is enough to enter the United States. Approvals earned elsewhere demonstrate that a product has been assessed somewhere, but they transfer no rights at the American border. Program planning should therefore never budget foreign approvals as substitutes for the FDA pathway; at best they are supporting evidence within it, and the schedule must reserve full time and cost for the American work itself.

Insight two: foreign manufacturing facilities carry three extended duties, namely FDA inspection, device tracking, and adverse event reporting.

FDA’s official pages make clear that foreign manufacturing facilities are subject to FDA inspection, to device tracking where applicable, and to adverse event reporting. This means the duty lists of foreign and domestic enterprises are fully aligned; foreign status brings no relief. What the foreign status does change is the logistics: inspection preparation, records retrieval, and event reporting all have to function across time zones and languages, often through the US Agent and the Official Correspondent. A facility that maintains its QMSR documentation, complaint files, and DMR and DHR in a permanently retrievable state will find an inspection a routine event rather than a crisis, and that state of readiness is built during normal operations, not assembled when notice arrives.

Insight three: the seven obligations form a series, and a gap in an earlier item blocks the later ones.

No US Agent means registration cannot be completed; registration not in place means listing is not accepted; and without registration and listing, import triggers detention without physical examination under Import Alert 99-34. If any link in the chain breaks, the goods do not enter. This is precisely why the seven obligations are best drawn as one diagram rather than seven parallel checklist items: the diagram shows which failures propagate downstream and which are contained, and it makes the monitoring priorities obvious. The first three nodes, the US Agent, registration, and listing, deserve the closest ongoing attention because everything behind them depends on their continuous validity.

4. Practical recommendations

• Manage the obligations with a series diagram rather than a parallel list, and monitor the three front nodes, the US Agent, registration, and listing, most intensively.
• Build an inspection-readiness package for each foreign manufacturing facility: QMSR documentation, complaints and CAPA, and the DMR and DHR, all retrievable on demand.
• Assign all seven obligations to one accountable owner supported by a single annual calendar, so that renewals and updates never fall between functions.
• Impose the same seven-obligation requirements on contract manufacturers, and obtain their registration numbers and listing numbers for the file.

5. Verification checklist

• □ A US Agent has been designated and written consent has been obtained.
• □ Establishment registration has been completed and the registration number obtained.
• □ Device listing has been completed and the listing number obtained.
• □ The QMSR system has been established and records are retained.
• □ The 510(k) or PMA pathway has been determined, or exemption has been confirmed.
• □ Labeling and UDI compliance has been completed.
• □ An MDR reporting and event file mechanism has been established.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com